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Abstract: The onset of cardiomyopathy is a common feature in sepsis, with relevant effects on its
pathophysiology and clinical care. Septic cardiomyopathy is characterized by reduced left ventricular
(LV) contractility eventually associated with LV dilatation with or without right ventricle failure.
Unfortunately, such a wide range of ultrasonographic findings does not reflect a deep comprehension
of sepsis-induced cardiomyopathy, but rather a lack of consensus about its definition. Several echocardiographic parameters intrinsically depend on loading conditions (both preload and afterload) so
that it may be challenging to discriminate which is primitive and which is induced by hemodynamic
perturbances. Here, we explore the state of the art in sepsis-related cardiomyopathy. We focus on
the shortcomings in its definition and point out how cardiac performance dynamically changes in
response to different hemodynamic clusters. A special attention is also given to update the knowledge
about molecular mechanisms leading to myocardial dysfunction and that recall those of myocardial
hibernation. Ultimately, the aim of this review is to highlight the unsolved issue in the field of
sepsis-induced cardiomyopathy as their implementation would lead to improve risk stratification
and clinical care.
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1. Introduction
Since 2016, sepsis has been defined as life-threatening organ dysfunction caused
by a dysregulated host response to infection [1]. Such a paradigm shift emphasizes the
supremacy of the non-homeostatic host response in infection pathophysiology. Septic
patients may be now further categorized in different multidimensional phenotypes: at
least four have been identified, not homologous with traditional patient clustering, but
strongly correlated with patterns of host immune response and clinical outcomes [2].
When enduring, an inflammatory state may lead to persistent organ injury, and long-term
mortality—even by several months to years—in elderly with highly comorbid conditions [3].
Meanwhile, a growing body of evidence is challenging the traditional view on septic cardiomyopathy. Historically assumed as adaptive response to intravascular hypovolemia,
cardiac performance actually changes dynamically in accordance with different hemodynamic clusters [4]. Myocardial dysfunction is commonly found in sepsis and outlined
by cellular abnormalities, circulating mediators and instrumental parameters. However,
whether the degree of myocardial dysfunction is related to systemic organ failure and the
extent to which sepsis-induced cardiomyopathy contributes to the outcome remains uncertain and somehow contradictory. This review article aims at summarizing the definition,
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epidemiology, pathophysiology, and diagnosis of septic cardiomyopathy. A special focus
will be paid at identifying and addressing major clinical shortcomings.
2. Definition and Epidemiological Considerations
2.1. Challenges in Defining Septic Cardiomyopathy
Septic cardiomyopathy was first described in 1921—before the advent of antibiotics—by
E. Romberg, in his Lehrbuch der Krankheiten des Herzens und der Blutgefäße (Textbook of
Diseases of the Heart and Blood Vessels) as septische akute Myokarditis (septic acute myocarditis). It may be broadly defined as an acute cardiac dysfunction unrelated to ischemia
that manifests in different ways: arrhythmias, left and/or right ventricular impairment
during systole or diastole, with or without reduction in cardiac output [5–7] (Table 1).
Table 1. Definition of septic cardiomyopathy.
Refs

Phenotypes

Diagnostic criteria for sepsis-associated
cardiac dysfunction unrelated to ischemia *.
Beesley et al., 2018 [5]
Martin at al., 2019 [6]

Cardiovascular phenotypes of septic
cardiomyopathy classification performance
Geri et al., 2019 [7]

Defining Criteria

(i)

LV dilatation with normal- or
low-filling pressure

NA

(ii)

Reduced LV ventricular
contractility

LVEF < 40–50%, ↓ LVFAC

(iii)

RV dysfunction of LV (systolic or
diastolic) dysfunction with
reduce response to fluid challenge

LVEF < 40–50%, ↓ LVFAC, e’ velocity, MPI,
Afterload-related cardiac performance,
Ventricular arterial decoupling

(i)

well resuscitated without
myocardial dysfunction or fluid
responsiveness

–

(ii)

LV systolic dysfunction

LVEF < 40%, LVFAC < 33%, aortic VTI < 14 cm

(iii)

Hyperkinetic profile

Aortic VTI > 20 cm, LVFAC > 58%,
heart rate < 106 bpm

(iv)

RV failure

RV/LV EDA > 0.8, sBP < 100 mmHg, dBP
< 51 mmHg

(v)

persistent hypovolemia

Aortic VTI < 16 cm, E wave < 67 cm/s,
∆DSVC > 39%

* One or more of these characteristics may define septic cardiomyopathy. LV: left ventricular; LVEF: left ventricular
ejection fraction; LVFAC: left ventricular fractional area change; RV: right ventricle; MPI: myocardial performance
index; MVG: myocardial velocity gradient; STE: speckle tracking echocardiography; VTI: velocity-time integral;
EDA: end-diastolic area; sBP: systolic blood pressure; dBP: diastolic blood pressure; ∆SVC: respiratory variations
of the superior vena cava.

Progress in cardiac imaging now makes available several parameters of cardiac
performance—historically limited to ejection fraction assessment—but they have paradoxically increased the uncertainty on how to precisely define septic cardiomyopathy.
Further issues challenging a global consensus on septic cardiomyopathy include: (i) the
potential role of cardiovascular background as premorbid cardiac status; (ii) the need of
assessing cardiac function in a setting of highly variable conditions, as determined by
inotrope use, autonomic dysregulation of heart rate/arrhythmias, fluid challenge, rise in
lactate and reduction in mixed venous oxygen saturation (Figure 1) [5–7]. Differentiating
septic cardiomyopathy from Takotsubo cardiomyopathy is another relevant clinical issue.
Although sepsis and septic shock may trigger Takotsubo cardiomyopathy, the underlying
myocardial alterations are different. Furthermore, myocardial dysfunction in Takotsubo cardiomyopathy typically has a regional distribution, mainly an apical ballooning mimicking
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acute coronary syndrome. Yet, a right ventricular dysfunction cannot be ruled out. Furthermore, Takotsubo cardiomyopathy shows a normalization within days or weeks, altacute coronary syndrome. Yet, a right ventricular dysfunction cannot be ruled out. Furtherhough patients may suffer a worse prognosis [8–14]. The extent to which septic cardiomymore, Takotsubo cardiomyopathy shows a normalization within days or weeks, although
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2.2. Epidemiology of Septic Cardiomyopathy
Studies on septic cardiomyopathy report a broad range of prevalence ranging from
10% to 70%. Lacking a broad consensus on definition, the epidemiology of septic cardiomyopathy remains elusive. Such a variability reflects the definition used in study designs
and the burden of confounding factors: male sex, age, high lactate levels at admission and
pre-existing cardiac performance [5]. Long-term effects of septic cardiomyopathy are also
poorly addressed but the prevalence of mortality seems to be higher [17] and characterized
by a U-shaped non-linear distribution [18]. The timeline raises further issues. The relatively
few studies published before and after the Third International Consensus Definitions for
Sepsis and Septic Shock (Sepsis-3) are potentially biased in patient selection [17,19,20].
Most of the them are limited to the setting of intensive care unit (ICU), where patients are
somehow selected and largely differ from those admitted in internal medicine wards in
terms of comorbidities, standards of care and outcome. Cumulative rate of sepsis admitted
to the ICU is indeed quite low (44 vs. 367 cases per 100,000 adult/year) [21] and patients
are generally younger and with better baseline myocardial performance. Of note, the risk
of cardiomyopathy seems to be higher in ICU, as older comorbid patients admitted to
internal medicine wards are likely to die before developing cardiac dysfunction. Based on
the above considerations, a consensus definition of septic cardiomyopathy is claimed as a
milestone for future studies.
3. Pathophysiology of Septic Cardiomyopathy
Endothelial, metabolic, and immune response abnormalities are generally involved in
the pathogenesis of ventricular dysfunction and arrhythmias during sepsis, whereas the
potential role of myocardial ischemia seems limited. Impaired blood flow autoregulation
in coronary microcirculation and altered metabolism of lactate, free fatty acid, and glucose
likely play a leading role. Septic myocytes may indeed switch their primary energy
substrate from free fatty acids to glucose with detrimental effects on contractility, similarly
to that observed during post-ischemic myocardial hibernation [22]. However, the transition
point from a protective to an adverse and maladaptive process is missing the humoral
response in sepsis (Figure 2).
3.1. Inflammatory Pathways and Cardiomyocyte Dysfunction
The hyperinflammatory—not counterbalanced—response is historically reported as a
paradigm of sepsis. Early clinical trials then focused on blunting inflammatory response by
common anti-inflammatory drugs such as glucocorticoids, non-steroidal anti-inflammatory
drugs or target therapy, with very limited results [23]. The extreme variability in pro-/antiinflammatory balance and the wide number of molecular pathways may explain such
disheartening results [24,25]. Ancestral signals released by pathogens (pathogen-associated
molecular patterns, PAMPs) or by damaged host tissues (damage-associated molecular patterns, DAMPs) and receptors such as Toll-like receptors (TLRs) trigger multiple intracellular
pathways, including the activation of nuclear factor-kB (NF-kB) and mitogen-activated
protein kinase (MAPK) [26–28]. The DAMPs with a recognized role in the pathophysiology
of septic cardiomyopathy include: heparan sulphate, which increases intranuclear transcription of pro-inflammatory cytokines and vascular permeability [29]; high mobility group
protein B1, which induces loss of calcium from sarcoplasmic reticulum [30]; and histones,
which are able to interfere with the production of cellular ATP by reducing mitochondrial
membrane potential and causing LV dysfunction and arrhythmias [31]. Among PAMPs,
bacterial lipopolysaccharide (LPS) partially mimics hemodynamic effects of septic shock
when administered to animal models or humans [32,33]. Detrimental effects of endotoxemia on cardiac contractility are largely due to mitochondrial dysfunction that leads to
abnormal calcium handling, disruption of ATP synthesis, endothelium reticulum stress, and
autophagy. Furthermore, LPS leads to electrophysiological dysfunctions through a both a
direct and cytokine-mediated effect on sodium current kinetics and non-selective cation
channel transient receptor potential vanilloid 1 (TRPV1) [34–37]. Furthermore, LPS and its
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downstream mediator TNF-α, IL-1β, IL-6, and C5a and ROS [38,39] critically alter calcium
(Ca2+ ) homeostasis by blunting the amplitude of intracellular currents and concentrations.
Dysfunction of intracellular calcium transporters and decreased calcium sensitivity in
cardiac myofilaments (due to phosphorylation of inhibitory troponin I) are cornerstones of
the impaired excitation-contraction coupling. Ultimately, endotoxemia impairs sarcolemma
diastolic Ca2+ extrusion with consequent overload [40–43] that determines systolic and
diastolic dysfunction during sepsis [44,45]. The characteristic delayed reversibility of septic
cardiomyopathy might be explained by the synthesis of new myofilaments to replace the
previously phosphorylated (and therefore inactive) ones.
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of cardiomyocytes [49], and its inhibition showed protective effects [50]. C5a is so far
the only complement factor with reported direct myocardial depressive effect, despite
several cardiac enzymes related to cardiac dysfunction during sepsis, such as serca2, NCX
and Na+ /K+ -atpase, which are complement receptor dependent [51]. Finally, adhesion
molecules take part in homing mechanisms and are upregulated during inflammatory response. In murine coronary endothelium and cardiomyocytes, specific adhesion molecules
were upregulated after LPS and TNF-α infusion. Moreover, the use of antibody blocking
these molecules such as anti-Intercellular adhesion molecule-1 (ICAM-1) and vascular
adhesion molecule-1 (VCAM-1) showed to prevent myocardial neutrophil accumulation
and cardiac dysfunction in animal models of sepsis [52]. On the contrary, neutrophils
depletion did not protect against myocardial dysfunction during sepsis, suggesting their
lesser cardiotoxic potential.
Nitric oxide (NO) is synthesized by nitric oxide synthase (NOS) in different cells of the
CV system including cardiac myocytes, and it exerts important roles in maintaining tissue
homeostasis by reducing oxidative stress. Indeed, via the cGMP pathway, NO regulates vascular tone, has an antioxidant effect, inhibits leukocyte and platelet adhesion to the endothelium,
and increases myocardial contractility [53]. Inflammation and oxidative stress show deep
interplay, fueling each other and facilitating the onset of deleterious vicious circles in different
diseases including sepsis. Differently from its endothelial and neuronal isoforms, inducible
NOS (iNOS) is not constitutively active and when highly expressed is a major responsible for
vasodilatation and hypotension in shock [54]. Indeed, iNOS can produce large amount of NO
when an inflammatory response occurs [55]. Sepsis leads to overexpression of iNOS not only
in immune cells but also in the myocardium [56]. Such increased expression has detrimental
effects on contractile function of cardiomyocytes, in part through the paradoxical induction of
reactive oxygen species (ROS), i.e., peroxynitrite [57], in part through the down-regulation of
adrenaline receptors and decreased sensitivity to calcium [29]. Confirming the important role
played by iNOS in myocardial dysfunction during sepsis, several non-specific anti-NOS drugs
such as melatonin and methylene blue showed beneficial effects in terms of cardiovascular
function and prognosis in preclinical studies [57,58].
3.2. Adrenergic System
Increased activation of the sympathetic system is a major compensatory reaction to
septic-related vasoplegia. During sepsis, β-adrenergic receptors (βARs) are downregulated, and the responsiveness to catecholamines is reduced in the whole cardiovascular
system [59,60]. When persistent, this adaptive response become maladaptive [61]. In myocardial tissue, excessive stimulation of cardiac βARs suppresses their expression and leads
to an inhibitory response with reverse of adrenergic G protein coupling [62], intracellular
calcium overload [63], increased production of ROS [64], disruption of membrane potential
via the inhibition of Na+ /K+ -ATPase pump [65], and induction of apoptosis [66]. A relevant role is played by Cardiac G Protein-Coupled Receptor Kinase 2 (GRK2). They are
the major negative regulators of βAR pro-contractile signal in sepsis-induced myocardial
dysfunction [67] and other different cardiac diseases including chronic heart failure and
Takotsubo syndrome [68].
3.3. Microvascular Dysfunction and Vasoactive Peptides
Activation of endothelial cells in consequence of an infective stimulus leads to the
synthesis of inflammatory cytokines, increased expression of cell adhesion molecules, loss of
the barrier function by glycocalyx shedding, edema, apoptosis, hypercoagulative state and
vasoplegia [69]. Several endogenous vasoactive peptides generate and maintain endothelial
dysregulation. LPS and cytokines up-regulate cyclooxygenase (COX)-2 (inducible form)
and then the production of prostanoids from arachidonic acid. This process mainly occurs
in inflammatory cells, myofibroblasts, endothelium and even in cardiomyocytes (i.e., in
myocardial infarction) [70,71]. Elevated levels of prostanoids such as thromboxane and
prostacyclin are associated with coronary microvascular dysfunction [72]. However, clinical
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trials have failed so far in proving any beneficial effect of pharmacological COX inhibition
on coronary microvascular homeostasis in sepsis. Less is known about the potential role of
endothelin-1 (ET-1) in sepsis cardiomyopathy, whereas an increase has been reported in
chronic cardiac disease (i.e., heart failure) [73]. ET-1 would have a major role in infectious
disease, as a promoter of cytokines release, platelet aggregation and vasoreactivity [74].
In single mouse study, cardiac overexpression of ET-1 was associated with the onset of
severe sepsis cardiomyopathy, characterized by interstitial infiltration of macrophages and
T lymphocytes and increased levels of the pro-inflammatory cytokines TNF-α, INF-γ, IL-1,
and IL-6 [75].
3.4. Energetic Dysmetabolism
Sepsis is characterized by altered myocardial lipoprotein metabolism and mobilization
of triglycerides and free fatty acids to overwhelm the systemic suppression of energy
production [76]. Physiologically, about 70% of cardiac ATP is produced via lipid oxidation,
while the rest is produced via glucose oxidation. A minor part also derives from the
catabolism of lactate and ketone bodies. Under pathological conditions, glucose oxidation
becomes the prevalent energetic pathway [77]. During sepsis, a reduction in fatty acid
oxidation is not compensated by the increase in glucose catabolism due to altered insulin
action, exacerbation of the inhibitory effects of alternative substrates on glycolysis, and
blunted glycogen synthesis [78]. Several enzymes involved in intracellular cardiac fatty
acid mobilization and oxidation are also inhibited [79,80]. Cardiac transcriptional factors
associated with fatty acid oxidation, such as peroxisome proliferator activated receptors
(PPARs) are also suppressed in sepsis and their stimulation with PPARs agonists lead
to improved survival in septic mice [81]. Mitochondrial dysfunction further contributes
to the energetic failure in sepsis cardiomyopathy, thus being a non-negligible cause of
reduced outcome [82–84]. Inflammation and oxidative stress alter mitochondrial structure
determining swelling, cytoplasmic accumulation of denatured protein and lysosomal
lesions [85,86]. Such a damage interferes with the respiratory chain [87] with falling in ATP
synthesis, release of calcium and pro-apoptotic proteins [88]. The pro-oxidant environment
induced by endotoxemia also trigger cardiac mitophagy, a defensive mechanism for the
removal of damaged mitochondria [89]. The antioxidant N-acetylcysteine seems to have a
protective roles against contractile dysfunction and mitophagy. Even levosimendam in both
mice and human beings has beneficial effects due to calcium sensitization and antioxidant
properties [90]. Lastly, when the degree of mitochondrial dysfunction is mild, myocardial
hibernation may occur. This is an adaptive, self-protective mechanism during which all
functions get reduced. Such a downregulation of mitochondrial gene transcription has
been reported in sepsis cardiomyopathy [91] and represents a reversible condition that
improves together with the resolution of sepsis [84].
4. Clinical Diagnosis
A combination of clinical, biochemical and hemodynamic parameters is increasingly
described as the best approach to identify and stratify septic cardiomyopathy.
4.1. Doppler Echocardiography: From Classic to Innovative Assessment
Echocardiography is considered the first line approach for the global assessment of
patients with septic shock. The use of ultrasound in this field has progressed over years but
the application of echocardiography for diagnosis/monitoring of septic cardiomyopathy
remains challenging. The dependence on loading conditions is a not overcoming intrinsic
limitation for several echocardiographic parameters, which rather reflect the degree of fluid
resuscitation/vascular leak (i.e., preload) and vasoplegia/response to vasoactive drugs
(i.e., afterload) [7]. This is especially true for LVEF, traditionally considered the hallmark of
septic cardiomyopathy. Indeed, merely identifying low LVEF (<50%) during sepsis does
not have predictive value in these patients [92]. Rather, LVEF would reflect the abovementioned U-shaped non-linear distribution. Indeed even a hyperdynamic LVEF—mostly
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expression of reduced afterload—is burdened by higher short-term mortality [93]. As partially afterload-independent measures, tissue Doppler imaging (TDI) and speckle-tracking
echocardiography (STE) are promising candidates. Unlike the peak systolic velocity of
the mitral annulus (referred to as S’) [20], the global longitudinal strain (GLS) is substantially more performing. GLS is a semi-automated algorithm tracking selected region of
myocardium during cardiac cycle (more specifically the ratio of the maximal change in the
myocardial longitudinal length in systole to the original length in diastole). GLS may detect
the impairment of LV systolic function before LVEF declines and worse GLS values are associated with higher mortality in patients with severe sepsis and septic shock [94]. Looking at
the future, coupling afterload and cardiac performance might optimize echocardiographic
assessment by overcoming this critical bias.
A rise in end-diastolic volume is common in septic shock patients—especially in
those receiving large volemic replacement—and likely associated with poor outcome. The
rationale for considering diastolic dysfunction in sepsis-induced cardiomyopathy relies
on the upstream effect on pulmonary circulation, right heart, and finally tissue edema.
However, the mining of diastolic dysfunction in sepsis cardiomyopathy remains to be
elucidated. The concept of sepsis-induced cardiomyopathy is originally based on the
abnormal LV function, but the risk ratio of patients with concomitant diastolic dysfunction
is not yet established. In particular, the TDI-derived velocity of the mitral annulus during
early diastole (e’)—considered relatively preload independent—and the ratio with the
peak of trans-mitral inflow velocity (E) are substantially associated with mortality [95].
However, pathophysiological and therapeutic implications of diastolic dysfunction are still
weak. The assessment of diastolic function is not yet validated for critically ill patients, and
data extrapolation is very challenging when the increase in LV end-diastolic pressure is
influenced by underlying cardiac performance (frequently unknown) and a variable degree
of fluid resuscitation/vascular leak). Furthermore, mitral annulus velocity is influenced by
heart rate in hyperdynamic cardiac output.
Right ventricle (RV) dysfunction is increasingly being reported in patients with sepsis.
It can be defined as a fractional area change (FAC) less than 35% or tricuspid annulus systolic
plane excursion (TAPSE)—the most reproducible measure—less than 16 mm. Systolic RV
pressure may also be easily calculated from tricuspid regurgitation flow. RV dysfunction is
common in severe sepsis/septic shock. Its prevalence ranges from 40% to 60% at admission
but significantly increase when the enrollment lasts up to 72 h. RV dysfunction correlated
with longer stay in ICU, and independently associated with higher risk of both early
and long-term mortality [96–98]. Nevertheless, conflicting results exist and the complex
geometry of RV—alongside the tight ventricular interdependence—raises many questions.
RV is a thin-walled structure facing off a high-compliance/low-resistance pulmonary
circulation. In sepsis, a paradoxical increase in pulmonary vasculature resistance may
occur, due to hypoxic vasoconstriction, pulmonary source of infection/acute respiratory
distress syndrome (ARDS), hypercapnia, and mechanical ventilation. Fluid overload
further increases the preload on RV, leading to isolated RV dysfunction. In addition, LV
dysfunction remains the leading cause of RV dysfunction and the association with poor
outcome might be rather a “false positive” [99].
4.2. Cardiac Performance
The afterload-related cardiac performance (ACP) is a relative old concept firstly introduced in 2011 and defined as [100]:
ACP (%) = COmeasured /COpredicted × 100%
In turn, Cardiac Output (CO)predicted may be calculated as a function of systemic
vascular resistance (SVR):
COpredicted = β0 × SVRβ1 (β0 = 394.07, β1 = −0.64)
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In preliminary studies, ACP estimation correlates with both APACHE II and SOFA
scores, even improving mortality prediction in both early and late stages of sepsis. ACP is now
considered as valid prognostic marker in sepsis and septic shock, ACP values lower than 80%
are associated with a higher risk of mortality in septic patients [101,102]. When defining septic
cardiomyopathy by ACP (<80%), a recent study from Wilhelm and coll. reported that about
50% of patients with septic shock have at least a moderate septic cardiomyopathy, and that
the lower the ACP the higher is mortality in this group of patients [103]. While validation in
larger studies is needed, the use of a machine learning approach to implement this algorithm
might further improve the model’s performance. Diameter and collapsibility of inferior vena
cava and B line quantification at lung ultrasound are further intriguing surrogate measures of
cardiac performance that deserve future investigations.
4.3. Biomarkers
The lack of a consensus definition and the uncertainties on pathophysiology of septic
cardiomyopathy makes it difficult to identify and validate biomarkers of disease. Being
associated with cardiac injury, troponins and natriuretic peptides rise during sepsis and
correlate with the degree of myocardial dysfunction [104]. The mechanisms of troponin
release during sepsis remain to be fully elucidated, but inflammation, myocardial wall stress,
drug toxicity and kidney dysfunction rather than cell death are likely be implicated. Newly
developed echocardiographic parameters, including TDI e STE applied to both left and right
ventricles correlated with troponin levels [105], but their association with mortality likely
reflects the severity of disease rather than the effective degree of myocardial dysfunction [94].
Brain natriuretic peptides (BNP and NT-proBNP) are secreted by myocardial cells in
response to stretch. This would candidate BNPs as surrogate biomarkers of LV dysfunction.
A significant association with both systolic and diastolic LV dysfunction was actually—but
not unequivocally—demonstrated for BNPs. Preliminary data also link the rise in BNPs
with RV dysfunction [106]. However, increased BNP levels during sepsis may be due to
different conditions including lung involvement (e.g., source of infection, ARDS, mechanical ventilation), pre-existing cardiac dysfunction, and renal impairment. BNPs also failed
to predict the responsiveness to fluid challenge, and cannot be used as a reliable biomarker
of volemic status during severe sepsis/septic shock 98. Even concerning mortality, the rise
in BNPs is associated with higher risk in meta-analyses but with substantial heterogeneity
across the studies [107,108]. As for acute decompensated heart failure, serial measurement
of BNPs might improve the performance of these biomarkers and clarify whether the
prognostic value is specifically tied with cardiac dysfunction or rather with sepsis severity.
The emerging field of non-coding RNAs (ncRNAs) recently opened new scenarios
for modulation of inflammation in sepsis, including sepsis-related cardiomyopathy 101.
Among the wide array of ncRNA, a massive amount of experimental data concerns microRNAs (miRNAs) with good potential for clinical translation [109]. Among the growing
number of miRNAs with clinical interest for sepsis/induced cardiomyopathy, the best
predictors of cardiac injury are miR21-3p and miR-155, but correlations with myocardial
dysfunction degree are also reported for miR-135a and miR-494-3p.
The cytokine storm makes it difficult to identify biomarkers of sepsis cardiomyopathy
across cytokines/interleukins. A single observational study has reported an association
with IL-8 [110]. Something more might be expected from artificial intelligence in the
next future. Bioinformatics analyses has the potential for deciphering this complex signals. Tumor necrosis factor, Jak-signal transducer and activator of transcription (STAT),
hypoxia-inducible transcription factor-1, and their interactions are increasingly described
as crossroads of sepsis cardiomyopathy [111].
5. Conclusions and Outlook
The most important goal in the field of septic cardiomyopathy might be its recognition. The lack of a consensus definition led to divergence about its clinical relevance,
whereas the advance in echocardiographic technology/algorithm is worryingly—and
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paradoxically—tangling up the search for a general agreement. Of paramount importance
for standardizing the definition of septic cardiomyopathy would be to discriminate whether
this is primitive and how it can induce hemodynamic perturbances. In addition, the dynamicity of changes in myocardial function should be considered. There is also growing
awareness that mild declines in cardiac performance are rather to be considered as an
adaptive response. In line with these missing points, studies outlining treatment goals for
sepsis cardiomyopathy are lacking. The “early goal-directed therapy” still remains the
current approach, since 2001, although this was not confirmed in later clinical trials (e.g.,
ProCESS, ARISE, ProMISe) [112–114]. As for sepsis, infection control and optimization
of hemodynamic parameters are also considered the standard treatment for sepsis cardiomyopathy. Even the assumption of complete recovery in the long-term after the sepsis
need to be revised. Long-term outcomes need to be added in study protocols, and this
requires adequate infrastructures for monitoring cardiovascular health status after severe
sepsis/septic shock. Overall, those unsolved questions have so far limited any therapeutic implications. Implementing those unsolved issues might improve risk stratification
and ultimately promote the translation of therapeutic approaches now confined to the
experimental field.
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